Holen Sie sich die Stockscreener-App
1.97
7.51%
-0.16
Vorhandelsmarkt:
2.55
0.58
+29.44%
Schlusskurs vom Vortag:
$2.13
Offen:
$2.17
24-Stunden-Volumen:
1.19M
Relative Volume:
1.65
Marktkapitalisierung:
$142.42M
Einnahmen:
$208.60K
Nettoeinkommen (Verlust:
$-58.59M
KGV:
-2.1497
EPS:
-0.9164
Netto-Cashflow:
$-47.11M
1W Leistung:
+17.96%
1M Leistung:
+115.91%
6M Leistung:
+58.87%
1J Leistung:
+19.39%
1-Tages-Spanne:
$1.925
$2.21
1-Wochen-Bereich:
$1.635
$2.21
52-Wochen-Spanne:
$0.7113
$2.21
Inflarx Nv Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IFRX
Inflarx Nv
|
1.97 | 142.42M | 208.60K | -58.59M | -47.11M | -0.9164 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inflarx Nv Stock (IFRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-02-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-04-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-01-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-10 | Eingeleitet | Credit Suisse | Outperform |
| 2018-07-13 | Eingeleitet | BMO Capital Markets | Outperform |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-28 | Eingeleitet | SunTrust | Buy |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Inflarx Nv Aktie (IFRX) Neueste Nachrichten
InflaRx prices $150M stock sale to fund pipeline and working capital - Stock Titan
InflaRx Files Q1 2026 Financials with SEC via Form 6-K - TipRanks
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares - GlobeNewswire
Funded through 2029, InflaRx expands izicopan into kidney diseases - Stock Titan
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases - GlobeNewswire
InflaRx (NASDAQ: IFRX) cuts Q1 loss but flags going concern risk - Stock Titan
Top 5 Hot Penny Stocks to Buy Now - Insider Monkey
MSN Money - MSN
InflaRx NV expected to post a loss of 14 cents a shareEarnings Preview - TradingView
InflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical Study - TipRanks
Low reactive metabolite data support InflaRx (IFRX) oral C5aR1 drug - Stock Titan
InflaRx reports preclinical data on izicopan metabolite formation By Investing.com - Investing.com Australia
In liver lab tests, izicopan showed over 100-fold lower reactive conjugates - Stock Titan
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes - ChartMill
InflaRx regains Nasdaq compliance after shares trade above $1 - MSN
InfraRX Down Ahead of Next Quarterly Report - Baystreet.ca
IFRX - Finviz
InflaRx N.V. to Publish Q1 2026 Financial Results on May 7, 2026 - Quiver Quantitative
InflaRx to Report First Quarter 2026 Results on May 7, 2026 - ChartMill
InflaRx N.V. (NASDAQ:IFRX) Short Interest Update - MarketBeat
InflaRx (IFRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
InflaRx Regains Nasdaq Minimum Bid Price Compliance, Securing Listing Status - TipRanks
InflaRx (Nasdaq: IFRX) back in line with Nasdaq minimum bid price rule - Stock Titan
InflaRx regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Australia
Nasdaq closes InflaRx listing issue after stock holds above $1 - Stock Titan
InflaRx regains Nasdaq minimum bid price compliance - Investing.com
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - marketscreener.com
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
InflaRx Shareholders Approve Capital, Governance Changes and 2026 Incentive Plan at April AGM - The Globe and Mail
InflaRx (NASDAQ:IFRX) Coverage Initiated at Oppenheimer - MarketBeat
Oppenheimer Adjusts Price Target on InflaRx to $5 From $7, Maintains Outperform Rating - marketscreener.com
InflaRx receives Nasdaq notification - MSN
InflaRx (IFRX) investors back board authorities, article changes and LTIP 2026 - Stock Titan
Guggenheim reiterates Inflarx stock rating on AAV opportunity By Investing.com - Investing.com India
IFRX Reiterated by Guggenheim -- Price Target Maintained at $14 - GuruFocus
InflaRx's (IFRX) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Guggenheim reiterates Inflarx stock rating on AAV opportunity - Investing.com
InflaRx N.V. (IFRX) Stock Mean Reversion (-1.57%) 2026-04-20Community Watchlist - Xã Vĩnh Công
Guggenheim Maintains InflaRx N.V. (IFRX) Buy Recommendation - MSN
IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases - MSN
Is InflaRx N.V. (IFRX) stock gaining bullish momentum (Parabolic) 2026-04-18Open Stock Picks - Xã Châu Thành
Finanzdaten der Inflarx Nv-Aktie (IFRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):